Author: Marie Powers

  • Texas Tech blood substitute technology nearing commercialization

    Texas Tech, the Texas Tech University Health Sciences Center (HSC), and Dallas-based HemoBioTech are developing blood substitutes that meets more rigorous safety protocols instituted by the U.S. Food and Drug Administration. Tech has patented a method to ensure that bood substitutes do not contain pathogens that are associated with blood. Intrinsic toxicity of hemoglobin was a major cause of complications in first-generation substitutes. The technology developed at Tech enables the formulation of blood substitutes with different pharmacological characteristics so the product is safe when injected into the bloodstream, says Jan Simoni, DVM, principal investigator of Tech’s blood substitute program. Tech is trying to make a substitute for perfusion fluids, which are used in heart surgeries. Blood substitutes also could be used in times of war or catastrophe, when mass casualties occur. In addition, blood substitutes could be stored for six months before use, in contrast to human blood, which must be used within one month. Blood substitutes also could also be transfused without typing a patient’s blood.

    The next step is to perform preclinical and clinical animal trials, which will require $2 million to $3 million in funding for testing by an independent lab. If the capital is raised quickly enough, testing could begin within the year. HemoBioTech has licensed the technology for the blood substitutes, which address a market estimated at more than $25 billion. “We are very focused on holding [HemoBioTech] accountable to raise the capital and get this to market,” says David L. Miller, Tech’s vice chancellor of technology commercialization and economic development. Success in FDA animal trials would bring additional capital from investors, he adds, by helping to move the technology to the next level.

    Source: The Daily Toreador

  • Reap the benefits, avoid the pitfalls of provisional patent applications

    When used appropriately, provisional patent applications (PPAs) are an inexpensive way for technology transfer offices to protect IP while they begin to market it to outsiders. In addition, PPAs buy inventors and TTOs an extra year of time to further develop the science before a non-provisional patent application must be filed with the USPTO. However, legal experts emphasize that shoddily prepared PPAs can come back to haunt TTOs later on in the game. And some busy TTOs tend to lose sight of the fact that PPAs are, quite frankly, a waste of time and money when they are prepared so routinely that little thought goes into whether or not the underlying IP merits further development.

    It’s an easy trap to fall into because PPAs are much easier to draft than non-provisionals, and at a cost of less than $1,000 they are far cheaper to file. However, the low cost without the accountability can be a double-edged sword, stresses Libby Hart-Wells, PhD, executive director of commercial ventures and intellectual property at the University of Maryland in Baltimore. “The provisional is not examined. It just goes into a file at the patent office. It is a placeholder. You could literally submit a napkin to the patent office and they would put it on file with a provisional application number,” she explains. However, Hart-Wells urges TTOs to remember that if the IP turns out to be highly valuable, then the quality of the provisional patent application becomes very important. “If you have filed a document that is crummy, and it will be the foundation for your entire patent portfolio later, then you are building a house of cards,” she says. A detailed article on best practices for filing PPAs appears in the April issue of Technology Transfer Tactics. To start a subscription and access the full article, plus three years of archived articles filled with tech transfer success strategies, CLICK HERE.

  • U-Illinois signs IP license agreement with start-up Hoowaki

    The University of Illinois at Urbana-Champaign (U-Illinois) has inked a license agreement with Hoowaki, LLC, of Pendleton, SC, that allows the start-up to use nanotechnology developed in the laboratory of William P. King, PhD. The technology provides a method to manufacture microstructures that alter the surface properties of various materials. The microstructure manufacturing technology allows for the surface structure of manmade products to be molded in ways that replicate the micro- to nanometer-sized details found in nature. Surfaces of metals, ceramics, and polymers can be altered to affect appearance, color, friction, adhesion, lubrication, drag, and flow control.

    One potential application is to create super-hydrophobic materials, which are self-cleaning, reduce ice and mud buildup, and can be used to increase performance. Hoowaki focuses on surface transformation technology for clients in industries ranging from aerospace engineering to biomedical applications to consumer goods. The broad potential for microstructure manufacturing technology will allow Hoowaki to diversify its products and services, which include systems to make industrial tooling surfaces as well as custom surface design, surface engineering, and licensing of patterns.

    Source: BusinessWire

  • Hebrew-U researchers discover genetic key to improve taste, yields of tomato plants

    Researchers at the Robert H. Smith Faculty of Agriculture, Food, and Environment at Israel’s Hebrew University and the Cold Spring Harbor Laboratory (CSHL) in New York have achieved increased yields and improved taste in hybrid tomato plants. The researchers discovered the yield-boosting power of a single gene, which controls the timing determining when plants make flowers. The technology works in different varieties of tomato and across a range of environmental conditions. The discovery was patented by Yissum, the TTO for Hebrew-U, which is seeking potential partners for further development and commercialization. “This discovery has tremendous potential to transform both the billion-dollar tomato industry as well as agricultural practices designed to get the most yield from other flowering crops,” says Zach Lippman, PhD, assistant professor in CSHL’s Watson School of Biological Sciences and co-author of a paper describing the technology that appears in Nature Genetics.

    Lippman and colleagues made the discovery while hunting for genes that boost hybrid vigor, a breeding principle that spurred the production of hybrid crops like corn and rice a century ago. Hybrid vigor, also known as heterosis, is the phenomenon by which intercrossing two varieties of plants produces more vigorous hybrid offspring with higher yields. A theory for heterosis, supported by the Hebrew-U-Cold Spring discovery, postulates that improved vigor stems from only a single gene — an effect called “superdominance” or “overdominance.” The research team developed a novel approach to find such genes by turning to a tomato “mutant library” — a collection of 5,000 plants, each of which has a single mutation in a single gene that causes defects in various aspects of tomato growth, such as fruit size, leaf shape, etc. Selecting 33 mutant plants, most of which produced low yield, the team crossed each mutant with its normal counterpart and searched for hybrids with improved yield. The most dramatic example increased yield by 60%. The scientists are seeking to team up with agricultural companies to develop the hybrids for commercial use.

    Source: ScienceBlog

  • Verdant Ventures Advisors formed as tech transfer venture fund

    Tampa, FL-based Innovaro (formerly UTEK Corporation) has formed Verdant Ventures Advisors, LLC, as an independently managed tech transfer venture fund. “Verdant Ventures will enable Innovaro clients to have access to capital that we believe will help facilitate the transfer of technologies that have not yet attained a certain milestone or level of development maturity,” says Doug Schaedler, Innovaro CEO. “The underlying goal of this relationship is to further increase our clients’ commercialization success rates as well as increase the frequency of technology licensing for the company.”

    Verdant will take advantage of the breadth and depth of Innovaro’s contacts and networks with university TTOs, medical centers, federal research labs, and corporations. The new fund seeks to reduce the risk of investing in early-stage opportunities by capitalizing on its relationships with companies that specialize in tech transfer. Verdant then will add value to early-stage technologies by advising management teams and by continuing the development of the acquired science. Verdant also will seek to formulate and implement market strategies that may include outlicensing, selling, or incorporating a company to develop technologies in its portfolio.

    Source:  MarketWatch

  • Series of royalty rate references expands to five titles

    A popular series of royalty rate benchmarking references has been expanded to five titles with the addition of two market-specific editions focused on medical devices and computer and communications technologies, respectively. Authored by respected royalty rate and valuation expert Russell Parr — who has spent more than two decades gathering deal terms — each of the five editions goes beyond raw rates and data and puts each transaction in context, including descriptions of the licensed technologies, full compensation terms, identity of the licensor and licensee, transaction background and history, and market analysis and benefits of the licensed technology. The two newest editions are designed to allow for less expensive access for those with specific interest in those technology spaces. The five titles are:

    • Royalty Rates for Technology, 4th Edition
    • Royalty Rates for Pharmaceuticals and Biotechnology, 6th Edition
    • Royalty Rates for Technology: Medical Devices and Diagnostics Edition
    • Royalty Rates for Technology: Computer and Communications Edition
    • Royalty Rates for Trademarks and Copyrights, 4th Edition

    CLICK HERE for complete details.

  • Rice-U business plan competition awards $1 million in cash prizes

    The 10th annual Rice business plan competition (RBPC) — one of the largest and most lucrative academic start-up contests — awarded more than $1 million in cash and prizes to fledgling firms. Forty-two university teams pitched their technology business plans to more than 200 judges representing successful VCs, entrepreneurs, and business leaders. The teams competed in six categories: life sciences, information technology, energy, green tech, social ventures, and other technologies. Each team presented a 15-minute business plan, with the top six competitors vying for a grand prize valued at up to $385,000, including a $285,000 equity investment, $20,000 in cash, and more than $80,000 in business services, including office space, marketing support, and business mentoring. BiologicsMD, LLC, from the University of Arkansas won the grand prize and several other awards. The start-up has developed OsteoFlor, a medication that binds directly to bone to spur bone growth. The product requires less frequent dosing and is expected to have few, if any, side effects.

    Other top winners included:

    • Rebellion Photonics from Rice University, whose patent-pending technology allows a high-resolution, large format, hyper-spectral image to be taken instantaneously. The compact, portable device provides for real-time, on-site, optical chemical detection.
    • GlucaGo, LLC, from Indiana University and Purdue University, which specializes in solid to liquid drug storage and injection technologies to improve the storage and administration of injectable drugs.
    • * OrthoIntrinsics from London School of Economics and Rice University, which is developing a patent-pending device, PRIME, that can directly and accurately measure internal hand strength. Used as an outcome measurement tool, PRIME can improve clinical practice and promote evidence-based medicine.
    • * Ambiq Micro from the University of Michigan, whose energy-efficient microcontroller (MCU), the Ambiq MCU, requires 25-130 times less energy in sleep mode and four to 10 times less energy in active mode than today’s functionally equivalent MCUs.
    • Reveal Design from the University of Michigan, whose automated software solution can perform scalable and comprehensive verification of digital logic designs to customers in the integrated circuit (IC) design industry.
    • UCLA’s Biogas & Electric, LLC, which has developed BioCat, a patented, low cost nitrous oxide (NOx) reduction technology that can be used in conjunction with anaerobic digestion — the leading solution to methane emissions produced by a variety of industries.
    • Sun Yat-sen University’s Deli Worm, which has developed patent-pending biotechnology and a custom-designed automation system to mass produce live organic worm meals as a substitute for current fish meals, mitigating the depletion of fish stock.
    • Stanford’s C3Nano, Inc., which has developed a cross-cutting technology to increase the efficiency of thin film photovoltaic (PV) technology.
    • The University of Arkansas’ InnerVision, whose extreme-condition electronics improve the efficiency of electricity-generating turbines and reduce operating costs.
    • Rice’s infantAIR, whose continuous positive airway pressure system (CPAP), named Baby Bubbles, gently inflates the lungs of infants and increases oxygenation.

    Source: Rice Alliance

  • New Bayh-Dole style IP law to take effect in South Africa this summer

    A South African law regulating IP from the country’s publicly funded research is expected to take effect in June or July. The legislation is designed to protect research and ensure that its commercialization benefits the people of South Africa, according to McLean Sibanda, a senior patent attorney at the department of science and technology’s National Research Foundation. The final regulations are expected to be posted on the department of science and technology’s website and distributed to stakeholders by May 1 so that the public has a few months to become familiar with the law before it takes effect.

    In comments on the draft regulations, Rory Moore, director of the Intellectual Property and Technology Transfer Office at the University of KwaZulu-Natal, said, “The Act seeks to address the situation where intellectual property, developed by researchers, lies idle at universities or is sold off to private companies, often overseas, with no benefit accruing to the university, the government, or the South African people.” Moore said that legislation passed in the U.S. and U.K. during the 1980s returned ownership of IP — which had previously vested in government — to the universities. The intent of the South African legislation appears to move ownership from individual researchers up to the institutional level and to the government level, in some instances.

    Under the Act, each institution (universities, science councils, etc.) will have access to a TTO, which will determine whether identified IP, developed using public funds, is worth protecting and commercializing. If so, the institution can elect to assume responsibility for the costs and benefits of this protection, with some financial benefit passing to the researchers. Should the institution elect to forego the patenting and commercialization function, the National Intellectual Property Management Office (NIMPO) can elect to protect and/or commercialize the IP on behalf of the state. Should NIMPO pass up the opportunity to do this, the IP is then first assigned to any private entity co-funders of the IP and then to the creators of the IP. The Act rewards ingenuity and creativity by entitling inventors in an institution to a minimum of 20% of the gross revenues accruing to the institution for the first ZAR 1mn and a minimum of 30% of net revenues thereafter, according to Sibanda.

    Cristina Pinto, business development and commercialization manager at Wits Enterprise — the IP commercialization organization for the University of Witwatersrand — says the Act develops a greater awareness of the value of IP and the need to exploit technology to improve society. “It is anticipated that the development of such awareness within the South African research community will permeate the greater African research community,” she says. The Act also provides a legislative environment in which institutions can negotiate IP rights with private industry when the research has been partially publicly funded. Previously, a “take it or leave it” attitude by industry forced universities to sponsor research for private companies, Pinto says. Other pluses include the provision of an IP fund to assist institutions in obtaining statutory IP protections and the creation of opportunities for local companies — especially small firms — to commercialize IP.

    Source: Digital Journal

  • India to establish IP facilitation centers for small, medium businesses

    The Federation of Indian Chambers of Commerce and Industry (FICCI), in association with the Union ministry of micro small and medium enterprises (MSMEs), is establishing a string of IP Facilitation Centers to assist MSMEs across India in protecting their IP. The IP Facilitation Centers will offer services covering all aspects of IP rights. In addition to providing general advice about patents, trademarks, designs, and copyrights, the Center’s technical and legal experts will offer patent searches, patent drafting, patent and trademark prosecution, and facilitation in commercialization of inventions. During its first phase, FICCI will open the IP Facilitation Center head office in Delhi. As work progresses, FICCI expects to link the head office to state offices in Kolkata, Jaipur, Mumbai, Ahmadabad, Hyderabad, Chennai, and Bangalore. Foreign firms file 80% of India’s patent applications. Though the country’s small industries produce various innovations, they often fail to protect their IP due to lack of funding and lack of awareness about the need to protect their IP.

    Source: PharmaBiz

  • U-Houston inks agreements for high temperature superconducting wire

    The University of Houston (UH) has executed two license agreements with SuperPower, a wholly owned subsidiary of Royal Philips Electronics based in Schenectady, NY. The first covers the IP on second generation high temperature superconductor wire developed under a sponsored research agreement previously executed between the two organizations. Venkat Selvamanickam, PhD, professor of mechanical engineering and director of the Applied Research Hub of the Texas Center for Superconductivity at the University of Houston (TCSUH), leads the sponsored research program. The second agreement covers a fundamental composition of matter patent for a high-temperature superconductor that was discovered by Paul Chu, PhD, professor of physics at UH. Additional terms were not disclosed.

    UH and SuperPower are partners in a $3.5-million Emerging Technology Fund award from the State of Texas to create the Applied Research Hub at TCSUH. In addition, the two organizations are partners in a $10.6-million Smart Grid Fault Current Limiting Superconducting Transformer Demonstration program funded by the U.S. Department of Energy.

    Source: EurekAlert!

  • UNC, Synereca execute first Carolina express license

    The University of North Carolina at Chapel Hill has executed the first Carolina express license agreement with UNC spinout Synereca Pharmaceuticals, Inc., also of Chapel Hill. The Carolina express license is a standard license agreement created by the University to foster more spinouts from academic research conducted on campus. (For an in-depth article on the Carolina express license, see the article in Technology Transfer Tactics, January 2010.) “We expect that Synereca is the first of many spinout companies from Carolina research that will use the Carolina express license,” says Cathy Innes, director of the University’s Office of Technology Development. Interested spinouts are prequalified to satisfy funding, business strategy, and management experience thresholds. “The response has been exceptionally positive across the academic technology transfer community as well as from our own faculty,” Innes says.

    Under the agreement, Synereca will license inventions resulting from research conducted by Scott F. Singleton, PhD, associate professor in the UNC Eshelman School of Pharmacy. Singleton’s research addresses bacterial resistance to current antibiotics. Synereca aims to develop orally active drugs that sustain the efficacy of existing antibiotics by inhibiting the bacterial enzyme RecA — a key factor in bacterial DNA repair and in the development and transmission of antibiotic resistance. Synereca’s prototype RecA inhibitors potentiate the killing of a variety of bacteria by a range of antibiotics, including a fluoroquinolone (ciprofloxacin) and penicillin (ampicillin) — representatives of antibiotic classes with combined annual sales exceeding $10 billion.

    W. Bennett Love, vice president for business operations at Synereca, says the Carolina express license reflects a well-conceived approach. “The qualification standards needed from a spinout company to satisfy the licensee requirements, combined with diligence commitments on the company’s part, insure that the university’s interests are well protected,” he says. “Yet the milestone parameters do not place an undue economic burden on the spinout company early in its development — the time when spinouts can least afford the cash drain. Additionally, having a set of standard terms in the agreement will materially shorten the time from company concept to realization.”

    Sources:  Triangle Business Journal and Synereca

  • Start-up boot camp webinar series offers virtual crash course for researchers, TTO staff

    Technology Transfer Tactics’ Distance Learning Division has just announced a six-week webinar series, Start-Up Boot Camp for University TTO Professionals and Inventors. This convenient format allows you cost-effectively educate both tech transfer staff and faculty innovators on the critical issues and success factors in forming and growing an academic spinout. 90-minute sessions will be held every Thursday from June 3rd through July 8th, featuring a faculty panel of high-level academic start-up experts. From early decision-making to exit strategies and each milestone along the way, this unique series is carefully crafted to provide the detailed guidance and advice neede to take start-ups beyond survival — to rapid growth, and ultimately to a liquidity event.

    Faculty include Gerard Eldering, founder and president of InnovateTech Ventures; Brian Cummings, executive director of the Technology Commercialization Office and VP for technology ventures at the University of Utah; Jack Brittain, the University of Utah’s vice president of Technology Venture Development; Jim Chung, director of the Office of Entrepreneurship at George Washington University; Kef Kasdin, general partner with Battelle Ventures and Innovation Valley Partners; Paul E. Rauch, PhD, founder of Evan Law Group LLC; and Charles Cella, patent attorney and co-founder of GTC.

    Attendees can select individual sessions as well as the entire series at a discounted rate, and series participants also receive the Start-Up Strategies book from Volume 2 of the Tech Transfer Library, plus the entire recorded webinar to share with staff and faculty who can’t attend the live sessions. CLICK HERE for complete details.

    And don’t miss these additional individual distance learning opportunities:

  • U-Alabama spinoff uses green tech to counter crop pest

    Birth control for moths — that’s one way to describe the focus of a start-up company based at The University of Alabama in Tuscaloosa that hopes to take a bite out of the $100 billion hole insects inflict each year on worldwide crop production. Rusty Sutterlin, PhD, a chemist and entrepreneur, and his newly formed company, Sutterlin Technologies, is targeting the brown codling moth — a pest to farmers around the planet — using an environmentally friendly, patent-pending biodegradable technology licensed from UA. Scott Spear, PhD, a research scientist in UA’s Alabama Innovation and Mentoring of Entrepreners (AIME) program, and colleagues developed the technology.

    Members of the company’s initial target market, apple growers, are primed and ready for relief from the winged insects, whose larva sometimes appears as worm-like creatures within apples. “The response I’m hearing indicates we can’t get this out soon enough,” Sutterlin says of his company’s powdery product, poised to enter field trials after successfully passing tests in UA laboratories. The product works by disrupting the insects’ mating patterns through the use of insect pheromones — chemical sex attractants that the tiny creatures emit to entice and locate mates. While using synthetic pheromones to reduce insect populations isn’t new, the standard means of delivering pheromones is quickly falling out of favor, Sutterlin says, because of environmental concerns and the labor-intensive steps necessary to use them.

    The company’s biodegradable approach centers around the use of pectin — a complex carbohydrate that occurs naturally in fruits, including apples, and some vegetables. Used in jam production to provide the jelly-like consistency, pectin is adept at binding with the pheromones and later releasing them it as it degrades harmlessly in the fields. “We take the pectin and chemically modify it,” Sutterlin explains. “Then, we add the insect pheromone, mix it together, do a little chemistry and, voila, we’ve encapsulated the pheromone in pectin. If you’re holding it in your hand, it looks almost like flour.”

    Growers can mix the powder with water and spray it on their fields using standard spraying equipment. As the pheromone is released, the insects are confused by the many scents that blanket the orchards and are unable to locate mates. “Growers are not going to see dead moths like they would with traditional insecticides,” Sutterlin says. Instead, “the mating season does not occur, so the next season, there are no bugs.” Unlike traditional insecticides, the technique doesn’t randomly kill harmless or commercially helpful insects and poses no environmental risks, he adds.

    Source: UA News

  • U-British Columbia receives patent for radiant energy vacuum dehydration technology

    The Canadian Patent Office has granted the University of British Columbia (UBC) a technology and process patent for the use of radiant energy vacuum (REV) dehydration technology in the production of dried biological materials. The patent covers vacuum microwave dehydration of a wide range of materials in solid, liquid, or frozen state, including enzymes, drugs, vitamins, antimicrobial agents and preservatives. The protected IP was developed in the laboratory of Tim Durance, PhD, professor and program director of food nutrition and health at UBC. Durance serves as chair and co-CEO of Vancouver-based EnWave Corporation, which has exclusively licensed the patent under an ongoing collaboration agreement with UBC. “This is a general, broad-based patent which serves to substantially bolster EnWave’s growing patent portfolio over the use of vacuum microwave dehydration technology globally,” Durance says.

    Using technologies developed in conjunction with UBC, EnWave is investigating new methods to apply REV technology, which combines microwave energy transfer under vacuum to dehydrate and alter structures and drive chemical reactions. REV technology creates unique product characteristics for both food products and medical applications, including fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines, and antibodies. In addition to the company’s patent filings on other REV dehydration processes and equipment, EnWave holds an exclusive worldwide license from UBC for a number of food and biopharmaceutical dehydration patents.

    Source:  Market Watch

  • Boulder Innovation Center shares tech transfer commercialization model

    For two years, the Boulder (CO) Innovation Center (BIC) has been a commercialization partner to 60 research teams through its partnership with the TTO at the University of Colorado-Boulder (CU). The BIC will now take its commercialization process to the tech transfer program at the Colorado School of Mines in Golden. “The relationship with the BIC increases the chances of commercialization by providing business mentorship, company formation, and risk capital financing,” says Tim Bour, executive director of the BIC. “This is the next step in technology transfer that the BIC now brings to the table.”

    The BIC has been working with Mines faculty on a number of projects, including technologies based around a nuclear battery for space applications, a nano thread for armor applications, and a process to convert CO2 to methanol. “Our mission is to help inventors and researchers at CU and Mines think about creating businesses based on their research and to introduce them to advisors with a proven track record in commercialization and potential investors,” Bour explains. As part of the partnership, the BIC will identify promising commercial applications at Mines and match Mines faculty and inventions with BIC mentors and advisors to assist in proof-of-concept proposal development, feasibility studies, business planning, and capital formation strategies.

    Source: PR Web


  • Outsourcing gains favor as option for improving productivity, deal flow

    Managing the growing volume of disclosures, patent filings, technology licenses, and spinoff activity is prompting some tech transfer managers to consider new tactics to handle more work without adding staff. Outsourcing is gaining interest as an option to shift service line responsibilities or IP portfolios to other entities, which may be located across the university or across the world. Texas Tech University in Lubbock is a typical example. Its Office of Technology Transfer and Intellectual Property, established in 1998 with a director and office assistant, initially was focused more on protecting than commercializing IP. In 2007, the university hired David L. Miller, JD, MBA, a serial entrepreneur, to manage the office. A year later, the department was renamed the Office of Technology Commercialization (OTC) and expanded to respond better to the needs of researchers, explains Amber Dean, associate managing director.

    Although the OTC now has five full-time staff, “compared to other universities our size we are still relatively small,” says Dean. Nevertheless, the OTC has significantly boosted production, increasing invention disclosures from 31 in 2006-07 to 61 in 2008-09 and more than doubling the number of license agreements while nearly tripling revenues. The OTC accomplished that growth, in part, by outsourcing segments of the tech transfer process to “fill some of the gaps” in its knowledge base while maintaining control of the mechanics of licensing and commercialization, according to Dean.

    Because business people rather than technicians staff the office, its biggest need is to evaluate new technologies for their technical merit and commercial potential. “Typically, we see about a third of our disclosures from our medical school, a third from our engineering school, and a third from our agriculture school,” Dean says. “Not one of us in our office has a particular background in those areas, so it was very important to find expertise in those fields to help us evaluate technologies.”

    Serendipitously, Newton F. Hamlin, a managing partner with Austin, TX-based LGE Execs, had previously approached Texas Tech officials to discuss strategies to increase the school’s technology commercialization prospects. LGE Execs is a network of more than 75 former top executives — mostly retired CEOs, presidents, CIOs, CTOs, CFOs, and others — with a track record of running companies, leading business units, growing start-ups, raising capital, and spearheading mergers and acquisitions. Following Hamlin’s initiative, the OTC established a formal relationship to assess promising new technologies. When the office receives a discovery, the staff sends a nonconfidential summary to Hamlin, who reviews the technology or forwards the idea to a colleague. The reviewer provides the OTC with an “opportunity rating” on a scale of A-F, based on the projected investment needed to achieve certain milestones, timeline associated with those milestones, and potential challenges associated with the technology’s development. The review weights each technology using criteria such as market size, urgency of the solution for the market, and strength of IP protection. If the rating is strong enough, the OTC begins to explore the possibility of forming a start-up.

    “There’s no charge, typically, for this type of review, so that’s a huge cost savings for our office,” Dean says, adding that outside consultants quoted the OTC fees of $3,500 and up per technology to conduct the same service. Once a technology receives a thumbs-up, the university licenses the technology to a start-up while Hamlin’s organization puts a management team in place and begins to raise money for a serious commercialization effort. A detailed article on TTO outsourcing strategies appears in the March issue of Technology Transfer Tactics. To subscriber and access the full article, along with a 3-year archive of tech transfer case studies, how-to strategies, and best practices, CLICK HERE.

  • U-Cincinnati licenses technology for research and genetic drug delivery

    The University of Cincinnati (UC) has signed worldwide exclusive license agreements with privately held Techulon, Inc., a life sciences company based at the Virginia Tech Corporate Research Center, to manufacture and sell transfection reagents used for research and therapeutic delivery of nucleic acids. The licenses cover a family of molecules invented by Theresa M. Reineke, PhD, while she was a faculty member in the chemistry department at UC’s McMicken College of Arts & Sciences. The university has filed two patent applications on the technology.

    Marketed by Techulon under the name Glycofect Transfection Reagent, the polymer-based formulations demonstrate efficacy for delivering genetic materials into a variety of cell types for health-related research and drug development. In contrast to currently used lipid-based transfection reagents, Techulon’s products are based on carbohydrate polymer structures invented by Reineke, now an associate professor of chemistry at Virginia Tech. “This new class of polymers can deliver DNA research reagents and therapeutics into a high number of cells and tissues types without causing cell damage or death,” Reineke explains. “After cellular delivery, the glycopolymers degrade and release their DNA cargo to perform its biological function without toxic side effects.”

    Glycofect is available for purchase as a transfection reagent for research applications, and Techulon plans to sublicense the reagent to companies seeking an efficient vector with low toxicity for therapeutic development, according to Frank Akers, the company’s president. Glycofect’s delivery, high gene expression, and low toxicity are particularly evident in primary cells, he adds. Current transfection reagents do not work well with primary cells, which are costly and difficult to obtain.

    Source: Genetic Engineering & Biotechnology News

  • U-Wisconsin start-up to commercialize nanotechnology

    A Milwaukee start-up founded by an engineer at the University of Wisconsin-Milwaukee (UWM) has completed a licensing agreement with the UWM Research Foundation for IP the company will use to develop nanoscale products and devices. NanoAffix Science LLC, founded by Junhong Chen, PhD, UWM associate professor of mechanical engineering, aims to commercialize Chen’s technologies, which include techniques to create custom nanoparticles and to deposit them onto carbon nanotubes. “We have found new ways of combining nanocomponents to produce valuable technologies which are superior to existing approaches,” Chen says. His methods of combining structures are low-cost but yield high-performance materials with potential uses in medical diagnostics, green energy technology, and sensors. The company plans to bring practical nanosensor products to market and to pursue other manufacturing technology applications, according to Ed Corrigan, NanoAffix director.

    Source: nano werk

  • Decision support software offers rapid, inexpensive due diligence reports for medical device technologies

    In partnership with e-Zassi, 2Market Information, publisher of Tech Transfer E-News, is offering half-price access to e-Zassi’s InnoVision Decision Support Software. This elegant tool for medical device developers and IP owners allows users to generate a 30- to 40-page report that both helps rapidly and efficiently triage your IP portfolio and instantly generate required due diligence data. Each report includes calculations of a new technology’s probable regulatory classification, clinical endpoints supporting the safety and marketing claims for market clearance, early stage clarity on the reimbursement and market landscape, and identification of the manufacturing, distribution, and sales burdens. The software includes membership in e-Zassi’s online medical device Business Network, so after the report is generated it can be posted and shared with potential partners and investors. InnoVision is a powerful, predictive analytical software tool that comprehensively analyzes medical device technologies at any stage of maturity, creating a roadmap for development and commercialization. Users gain a deep understanding of the potential burdens, opportunities, and requirements for development — while drastically reducing the time and expense associated with the due diligence process. For complete details, CLICK HERE.

  • UVA medical training simulator to aid prostate cancer screening

    Simulation technology developed at the University of Virginia (UVA) will allow health care providers and medical students to experience numerous scenarios that simulate prostate cancer. The Virginia Prostate Exam Simulator consists of an anatomical model with four different prostates that can be altered by the inflation and deflation of small water balloons. The interactive tool can simulate more than 100 malignancy scenarios, which might take years for clinicians to encounter through traditional patient examinations, says Marcus Martin, MD, UVA professor of emergency medicine, interim vice president, and chief officer for diversity and equity.

    The project’s goal was to create multiple conditions that could be reconfigured on demand by clinicians to simulate graded stages of cancerous tumors and benign prostatic hyperplasia in a lifelike model. “Collaboration helped us develop a realistic and robust simulator for teaching students and practitioner,” says Reba Moyer Childress, MSN, FNP, APRN-BC, assistant professor of nursing at UVA. “The simulator is user-friendly, accurate, and representative of how an actual patient will present.” Initially, training occurs in a supervised setting, followed by unsupervised scenarios. The simulator’s design enables immediate feedback to both the instructor and trainees. UVA researchers are developing additional simulators that will include refinements of the technology. The UVA Patent Foundation has licensed the technology to health care product supplier NASCO International.

    Source:  Medical News TODAY